Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04143594 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 183
- Enrollment target
NCT04143594 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 183 participants.
The verdict
NCT04143594, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 183 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the efficacy of lenacapavir (formerly GS-6207) containing regimens in people living with human immunodeficiency virus (HIV) (PLWH).
Interventions
- DRUG TAF
- DRUG Oral Lenacapavir
- DRUG Subcutaneous Lenacapavir
- DRUG F/TAF
- DRUG BIC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2019-11-22 |
| Est. Completion | 2023-09-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04143594
The ClinicalTrials.gov registry entry for NCT04143594 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 183 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which TAF is the first listed.
NCT04143594 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04143594 about?
NCT04143594 is a clinical study titled "Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV". The primary objective of this study is to evaluate the efficacy of lenacapavir (formerly GS-6207) containing regimens in people living with human immunodeficiency virus (HIV) (PLWH).
What is the current status of trial NCT04143594?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 183 participants. The study started on 2019-11-22. Estimated completion is 2023-09-19.
What interventions are being tested in trial NCT04143594?
The interventions under investigation include: TAF (DRUG), Oral Lenacapavir (DRUG), Subcutaneous Lenacapavir (DRUG), F/TAF (DRUG), BIC (DRUG).
Who is sponsoring clinical trial NCT04143594?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.